Antibody-drug conjugates (ADCs) are a new class of biotherapeutics, consisting of acytotoxic payload covalently bound to an antibody by a linker. Evaluating the pharmacokinetics (PK) properties of ADCs in preclinical and clinical studies is essential for their strategic design and successful development.
Anti-payload Antibodies: Facilitating ADC PK studies
Sponsored PublicationsAntibody-drug conjugates (ADCs) are a new class of biotherapeutics, consisting of acytotoxic payload covalently bound to an antibody by a linker. Evaluating the pharmacokinetics (PK) properties of ADCs in preclinical and clinical studies is essential for their strategic design and successful development.
Researchers present AI-guided protein design tool
Latest NewsDanish AI expert Francesco Pesce and collegues have expanded the toolbox for computational protein design. Their new algorithm will facilitate the design of proteins whose functions exploit the many properties afforded by protein disorder.
Amferia partners with Biokema expanding into Switzerland
Latest NewsSwedish antimicrobial specialist Amferia AB has inked a contract is with the Swiss animal health company Biokema SA for commercialisation of Amferia’s proprietary antimicrobial wound care technology in Switzerland.
Confusion in Germany about useful genetic testing
Latest NewsThe extent to which vested interests can delay innovation can currently be seen in the introduction of screening for the dominantly inherited disease familial hypercholesterolaemia, the benefits of which have already been proven in the UK and the Netherlands.
AAX Biotech strengthens Board of Directors
AppointmentsSwedish biotech company AAX Biotech AB has welcomed Patrik Strömberg as a new member of the Board of Directors.
AI identifies most effective climate policies
Latest NewsA brand-new AI analysis of 1,500 climate policies across 41 countries between 1998 and 2022 reveals that only 4% achieved significant emission reductions.
Vandria closes Series A round at CHF28.3m
Latest NewsSwiss mitophagy specialist Vandria SA has booted its CHF18m Series A financing from December 2023 by further CHF10.3m to push its lead VNA-318 to Phase Ib testing.
Adcendo broadens ADC pipeline in US$1bn biobucks deal
Latest NewsDanish ADC maker Adcendo ApS has licenced the rights to commercialise Multitude Therapeutics Inc’s first-in-class ADCE-T02 globally except the Greater China region.
Emfret presents novel anticoagulant
Latest NewsGerman biotech spin-out Emfret Analytics GmbH & Co. KG has presented a first in class anticoagulant that helps preventing heart attacks and stroke while showing less adverse effects than approved meds.
BioNTech: ADC study continues with conditions
Latest NewsGood news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue.